A prospective multicentre study on the safety of long-term intensive plasmapheresis in donors (SIPLA)

Vox Sanguinis

Volumn 91, Issue 2, 2006, Pages 162-173

  Schulzki, T ^a   Seidel, K ^b   Storch, H ^c   Karges, H ^b   Kiessig, S ^c   Schneider, S ^d   Taborski, U ^e   Wolter, K ^c   Steppat, D ^b   Behm, E ^c   Zeisner, M ^c   Hellstern, P ^f,g  

^a RBSD SRK Graubünden   (Switzerland)

^b ZLB Plasma Services GmbH   (Germany)

^c Baxter Deutschland GmbH   (Germany)

^d Institut fur Herzinfarktforschung   (Germany)

^e Deutsche Gesell fur Humanplasma   (Germany)

^f Inst Hemostaseology/Transfus Med   (Germany)

^g Academic City Hospital   (Germany)

Author keywords

Dropout predictors; Dropout rates and reasons; Intensive donor plasmapheresis; Safety

Indexed keywords

IMMUNOGLOBULIN G;

ADULT; ARTICLE; BLOOD DONOR; BODY WEIGHT; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; GENDER; HEALTH PROGRAM; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SAFETY; SOCIOECONOMICS;

ADULT; BLOOD DONORS; BODY WEIGHT; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PLASMAPHERESIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; SOCIOECONOMIC FACTORS; SURVIVAL ANALYSIS; SWITZERLAND; TIME FACTORS;

EID: 33746411466     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2006.00794.x     Document Type: Article

References (26)

1. US Food and Drugs Administration: Compliance Policy Guides Manual: Plasmapheresis - 48-Hour Period Between Plasmapheresis Procedures CPG 7123.23. Chapter 2, Subchapter 256.100. Rochester, MD, USA, 2000
2. US Food and Drugs Administration: Compliance Policy Guides Manual: Volume Limits for Automated Collection of Source Plasma. Chapter 2, Subchapter 252.110. Rochester, MD, USA, 2000
3. Council of Europe: Guide to the Preparation, Use and Quality Assurance of Blood Components, 11th edn. Strasbourg, Council of Europe Publishing, 2005
4. Lundsgaard-Hansen P: Volume limitations of plasmapheresis. Vox Sang 1977; 32:20-25
5. Lundsgaard-Hansen P: Intensive plasmapheresis as a risk factor for arteriosclerotic cardiovascular disease? Vox Sang 1977; 33:1-4
6. Tran-Mi B, Storch H, Seidel K, Schulzki T, Haubelt H, Anders C, Nagel D, Siegler KE, Vogt A, Seiler D, Hellstern P: The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk factors. Vox Sang 2004; 86:189-197
7. Bechtloff S, Tran-My B, Haubelt H, Stelzer G, Anders C, Hellstern P: A prospective trial on the safety of long-term intensive plasmapheresis in donors. Vox Sang 2005; 88:189-195
8. German Federal Medical Association and the Paul Ehrlich Institute: [Guidelines to Blood Group Determination and Blood Transfusion (Haemotherapy)]. Cologne, Deutscher Ärzte-Verlag, 1996
9. Rodell MB: Collection of source plasma from remunerated donors. Dev Biol Stand 1993; 81:57-64
10. Rodell MB, Lee ML: Determination of reasons for cessation of participation in serial plasmapheresis programs. Transfusion 1999; 39:900-903
11. Kliman A, Carbone PP, Gaydos LA, Freireich EJ: Effects of intensive plasmapheresis on normal blood donors. Blood 1964; 23:647-656
12. Simson LR, Lien DM, Warner CL, Oberman HA: The long-term effects of repeated plasmapheresis. Am J Clin Pathol 1966; 45:367-372
13. Cohen MA, Oberman HA: Safety and long-term effects of plasmapheresis. Transfusion 1970; 10:58-66
14. Salvaggio J, Arquembourg P, Bickers J, Bice D: The effect of prolonged plasmapheresis on immunoglobulins, other serum proteins, delayed hypersensitivity and phytohemagglutinin-induced lymphocyte transformation. Int Arch Allergy 1971; 41:883-894
15. Shanbrom E, Lundak R, Walford RL: Long-term plasmapheresis: effects on specific plasma proteins. Transfusion 1972; 12:162-167
16. Friedman BA, Schork MA, Mocniak JL, Oberman HA: Short-term and long-term effects of plasmapheresis on serum proteins and immunoglobulins. Transfusion 1975; 15:467-472
17. Löwel H, Engel S, Hörmann A, Gostomzyk J, Bolte HD, Keil U for the MONICA-Augsburg Myocardial Infarction Register Team: Acute myocardial infarction and sudden death from an epidemiological point of view. Intensivmed 1999; 36:652-661
18. Kolominsky-Rabas PL, Sarti C, Heuschmann PU, Graf C, Siemonsen S, Neundoerfer B, Katalinic A, Lang E, Gassmann K-G, Ritter von Stockert T: A prospective community-based study of stroke in Germany - The Erlangen Stroke Project (ESPro). Incidence and case fatality at 1, 3, and 12 months. Stroke; 1008:2501-2506
19. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, Folsom AR: Deep vein thrombosis and pulmonary embolism in two cohorts. The Longitudinal Investigation of Thromboembolism Etiology. Am J Med 2004; 117:19-25
20. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481
21. McCullough J: The U.S. blood supply system; in McCullough J (ed.): Transfusion Medicine. Philadelphia, Elsevier Churchill Livingstone, 2005
22. Code of Federals Regulations (CFR), Title 21 CFR Part 640. Washington, DC, US Government Printing Office, 2004
23. McLeod BC, Price TH, Owen H, Ciavarella D, Sniecinski I, Randels MJ, Smith JW: Frequency of immediate adverse effects associated with apheresis donation. Transfusion 1998; 38:938-943
24. Newman BH: Blood donor complications after whole-blood donation. Curr Opin Hematol 2004; 11:339-345
25. Kaplan RM, Anderson JP, Wingard DL: Gender differences in health-related quality of life. Health Psychol 1991; 10:86-93
26. Leveille SG, Resnick HE, Balfour J: Gender differences in disability: evidence and underlying reasons. Aging Clin Exp Res 2000; 12:106-112